Amgen Inc.

Mary Catherine Walton Cabrera

Qingyian Liu

Ana Elena Minatti

Jonathan Dante Low

Vu Van Ma

Matthew Paul Bourbeau

Jian Jeffrey Chen

Ning Chen

Jennifer Rebecca Allen

Thomas T Nguyen

Nobuko Nishimura

Qiufen May Xue

Liping H Pettus

Michael J Frohn

Nuria A Tamayo

Aaron C Siegmund

John Gordon Allen

James A Brown

Kexue Li

Lei Jia

Clifford Goodman

Abhisek Banerjee

Corey Reeves

Alfonso Pozzan

Iain Lingard

Federica Tonelli

Giulia Lattanzi

Sabrina Tassini

The present disclosure provides compounds useful for the inhibition of Delta-5 Desaturase (“D5D”). The compounds have a general Formula 1: wherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a metabolic or cardiovascular disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use

Compounds of formula (I): (I), as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.

KIF18A inhibitors

Growing community of inventors

Camarillo, CA, United States of America

Mary Catherine Walton Cabrera